Epstein–Barr virus (EBV) is a ubiquitous human lymphotropic herpesvirus with a well-
established causal role in several cancers. Recent studies have provided compelling …

Antagonistic antibodies targeting the inhibitory immune-checkpoint receptor PD-1 or its
ligand PD-L1 are used to treat a wide range of cancer types and can substantially improve …

The cytotoxic T-lymphocyte–associated antigen 4 (CTLA-4)/B7 and programmed death 1
(PD-1)/programmed cell death-ligand 1 (PD-L1) are two most representative immune …

Abstract Programmed death-ligand 1 (PD-L1) on cancer cells engages with programmed
cell death-1 (PD-1) on immune cells, contributing to cancer immune escape. For multiple …

The tumor microenvironment (TME) is a complex and ever-changing “rogue organ”
composed of its own blood supply, lymphatic and nervous systems, stroma, immune cells …

Epstein-Barr virus (EBV) is reportedly the first identified human tumor virus, and is closely
related to the occurrence and development of nasopharyngeal carcinoma (NPC), gastric …

During malignant transformation, accumulated somatic mutations endow cancer cells with
increased invasiveness and immunogenicity. Under selective pressure, these highly …

Epstein–Barr virus (EBV) infection is an established cause of nasopharyngeal carcinoma
(NPC) and is involved in a variety of malignant phenotypes, including tumor immune …

Purpose: miRNA-155 is an oncogenic miRNA highly expressed in B-cell malignancies,
particularly in the non–germinal center B-cell or activated B-cell subtype of diffuse large B …

Accumulating research suggests that the tumor immune microenvironment (TIME) plays an
essential role in regulation of tumor growth and metastasis. The cellular and molecular …